ABT-072 potassium trihydrate

For research use only. Not for therapeutic Use.

  • CAT Number: I045692
  • CAS Number: 1132940-31-8
  • Molecular Formula: C24H32KN3O8S
  • Molecular Weight: 561.69
  • Purity: ≥95%
Inquiry Now

ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC50=1 nM; HCV GT1b EC50=0.3 nM)[1][2][3].
ABT-072 (potassium trihydrate) is a non-nucleoside NS5B polymerase inhibitor with nanomolar potency in vitro against genotype 1a and 1b hepatitis C virus polymerases[1].
ABT-072 (5 and/or 30 mg/kg; i.v. or p.o.) (potassium trihydrate) shows good PK properties[3].
ABT-072 (2.5 and/or 30 mg/kg; i.v. or p.o.) (potassium trihydrate) shows low plasma clearance and high oral bioavailability[3].


Catalog Number I045692
CAS Number 1132940-31-8
Synonyms

potassium;[4-[(E)-2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethenyl]phenyl]-methylsulfonylazanide;trihydrate

Molecular Formula C24H32KN3O8S
Purity ≥95%
InChI InChI=1S/C24H26N3O5S.K.3H2O/c1-24(2,3)20-15-19(27-13-12-21(28)25-23(27)29)14-17(22(20)32-4)9-6-16-7-10-18(11-8-16)26-33(5,30)31;;;;/h6-15H,1-5H3,(H,25,28,29);;3*1H2/q-1;+1;;;/b9-6+;;;;
InChIKey YOVHIDHQVIZCEH-MPMAQEBPSA-N
SMILES CC(C)(C)C1=CC(=CC(=C1OC)C=CC2=CC=C(C=C2)[N-]S(=O)(=O)C)N3C=CC(=O)NC3=O.O.O.O.[K+]
Reference

[1]. Lawitz E, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol. 2013;59(1):18-23.
 [Content Brief]

[2]. Shi Y, et al. Assessing Supersaturation and Its Impact on In Vivo Bioavailability of a Low-Solubility Compound ABT-072 With a Dual pH, Two-Phase Dissolution Method. J Pharm Sci. 2016;105(9):2886-2895.
 [Content Brief]

[3]. Randolph JT, et al. Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem. 2018;61(3):1153-1163.
 [Content Brief]

Request a Quote